RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $830
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raised the price target from $820 to $830.
August 21, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regeneron Pharmaceuticals' price target has been raised from $820 to $830 by RBC Capital, maintaining a 'Sector Perform' rating.
The news of RBC Capital raising the price target for Regeneron Pharmaceuticals indicates a positive outlook for the company. However, the 'Sector Perform' rating suggests that the stock is expected to perform in line with the sector, indicating a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100